Neurocrine Biosciences and Voyager Therapeutics to expect IND filings in 2025

February 13, 2025. 

“We are encouraged that our novel TRACER capsids continue to perform consistently across multiple programs, and we believe they have the potential to transform gene therapy for CNS diseases. We continue to expect IND filings in 2025 for our gene therapy candidates for GBA1 and FA, and in 2026 for VY1706,” said Sandrock, Jr., in the press release

Neurocrine Biosciences and Voyager Therapeutics to expect IND filings in 2025